Clinical Services: Servic Name

Headline

Some Description

METRICS OR KEY SENTENCE ABOUT BENEFITS

Benefits, description etc.

Tools & TEmplate or featured Video or other Resource

Headline
Subheadline or sentence of some kind to describe
DOWNLOAD FACTSHEET
01.
Experienced Clinical Research Associates (CRAs)
Highly trained with deep scientific and clinical expertise, our CRAs thoroughly understand your investigational product, protocol, and regulatory landscape.
02.
Rigorous Clinical Trial Oversight
Our meticulous monitoring ensures trial data accuracy, completeness, and traceability, while maintaining strict adherence to protocols, GCP, and regulations
03.
Proactive Communication with Sites
Our team maintains constant communication with site staff to ensure timely data entry, resolve queries, and address any issues that arise during the trial.
04.
Customized Monitoring Plans
Our tailored monitoring plans outline specific monitoring methods, responsibilities, and requirements, addressing the unique risks and needs of your study.

Proxima's COmprehensive Monitoring approach

Our comprehensive monitoring approach includes on-site and remote visits, data verification, and detailed reporting.

We focus on identifying and mitigating risks, ensuring subject safety, and maintaining data integrity throughout the trial. Our monitors are adept at recognizing potential issues early and providing actionable insights to keep your trial on track.

Process Option One

Process Item Description
Learn More
Process Item Description
Learn More
Process Item Description
Learn More
Process Item Description
Learn More
Process Item Description
Learn More
01.
EARLY CLINICAL DEVELOPMENT
02.
CLINICAL CRO DELIVERY
03.
CONSULTING

Process Option 2

Our team of therapeutic and operational experts can support all aspects of clinical and commercial operations, allowing for easier innovation and earlier access to market.

Our trial delivery focuses on agility, efficiency, speed, and a deep understanding of cardiovascular endpoints. We work with class II and class III devices, whether they support a 510(k), PMA, post approval, or observational assessment.

Topic

Headline one
Headline two
Paragraph of descritpion
Partner with an expert that understands your innovation

Deliverables

Headline
Headline two
Main Topic
Item
Item
Item
Item
Item
Item
Item
Item
Main Topic
Item
Item
Item
Item
Item
Item
Item
Item
"The projects are very interesting as they deal a lot with niche products, and products that are seeking for a market. The people are fantastic, funny, open minded, tolerant, adorable, intelligent, competent, but above all they are motivated."
Position
First & Last Name
"The projects are very interesting as they deal a lot with niche products, and products that are seeking for a market. The people are fantastic, funny, open minded, tolerant, adorable, intelligent, competent, but above all they are motivated."
Position
First & Last Name
“As a busy surgeon developing a Class III implantable device I needed help with regulatory strategy and execution. I wanted someone that was as passionate about the device as I was and that could hit the ground running. Because PROXIMA supports emerging companies through Med Tech Innovator they were a perfect fit. Isabella also helped us manage other vendor relationships and kept things moving forward. I been very happy working with PROXIMA”
Founder
Marc Bessler, M.D.
We have had the pleasure of working with the Proxima team for over a year on overall regulatory strategy and support for FDA interactions. The entire Proxima team are unbelievably knowledgeable in this space with excellent communication skills, highly strategic thinking, and amazing customer service. We at Prenosis highly recommend them as a one stop shop for anything regulatory or clinical trial related, all offered at a very attractive price point.
CEO and Co-Founder
Bobby Reddy Jr.
Proxima was instrumental to our success in getting breakthrough device designation for our product! The team was very knowledgeable and responsive and set us up for success. They made the FDA process easy to go through and prepared us for future interactions with FDA.
Co-Founder
Jade Doucet-Martineau
We joined forces with Proxima's Quality Consultants to ready ourselves for upcoming audits of both our QMS and our parent company's QMS. Their approachable, expert team delivered essential support and insightful guidance, never shying away from directing us confidently towards the right path. We are proud to share our spotless ISO 13485 recertification audit, a testament to Proxima's steadfast commitment and fearless leadership!
Regulatory & QA Manager
Michael Selva
Developing medical technology for children has unique challenges. The Southwest National Pediatric Device Innovation Consortium (SWPDC) is a consortium supported by an FDA grant to assist innovators with their pediatric device development as well as address their regulatory challenges. Proxima has been a strong partner for us in helping guide innovators quickly through their regulatory and clinical journey.
Physician
Chester J. Koh, MD
“Proxima has been such a wonderful help every step of the way. Everyone is truly great to work with.”
Junior Project Engineer
Karen Wells
"The wonderful people at Proxima have been dogged champions for our success. Aside from being deeply experienced in our particular field and keenly knowledgeable on developing trends they take our success as personally as we do. That, as much as anything, has been the difference."
COO & Co-Founder
Geoffrey Lucks
"Proxima has been attentive to a variety of our regulatory related needs. From coordinating studies with aggressive timelines to assisting with sales aid approvals, they have always delivered. As we launched our first in class/disease product, we needed a high touch clinical research and regulatory partner, and Proxima has provided that for us."
Founder & CEO
Robert Whitehead
Proxima has been an important piece of Memgen's regulatory and clinical achievements for multiple years now, playing a vital role in our IND approval, clinical launch, and trial management of our first-in-human study of our lead cancer immunotherapy biologic. Proxima and its growing team have continually shown their experience, broad skill sets, adaptability to our company's needs and objectives, and value in an industry with a myriad of CROs to choose from.
CSO
Mark Cantwell
Headline for CTA
Some kind of CTA continuation
Speak with a [SERVICE] expert

FREQUENTLY ASKED QUESTIONS

Are research sponsors obligated to determine IRB compliance with regulations?
Learn More

Glossary

Medical Device Reporting (MDR)
Learn More

Latest INsight

Global Medical Device Podcast: Understanding and Handling Different Types of Feedback
Learn More

Latest Video

What Is Substantial Equivalence?
Learn More